Pleased to share results from the CAcTUS Phase II trial of ctDNA-guided therapy in BRAF-mutant advanced melanoma are now published! 🌵🧬 CAcTUS is the first melanoma trial to adapt treatment based on ctDNA testing. Read: www.nature.com/articles/s41...
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial - Nature Communications
Targeted therapy (with BRAK and MEK inhibitors) and immune checkpoint blockade have improved survival for patients with advanced BRAF-mutant cutaneous melanoma, however, the optimal scheduling for the...
nature.com